安德罗格拉福利德衍生物CX-10通过调节自和细胞应激来缓解性结肠炎
Zhengshi Chen1, Yongheng He2, Yi Hong2
1Department of Anorectal, Tongde Hospital of Zhejiang Province, Gucui Road, Hangzhou, Zhejiang Province, 310000, China.
Journal of clinical biochemistry and nutrition
|August 8, 2025
概括
来自andrographolide的新型化合物CX-10通过减少炎症和氧化应激,有效治疗性结肠炎 (UC). 这项研究表明,CX-10在小鼠模型中恢复了自并减轻了疾病活动,为新的UC疗法提供了潜力.
科学领域:
- 胃肠病学和肝病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 带来了重大的临床管理挑战,许多患者对当前的治疗方法没有反应.
- 了解UC的病原性,特别是炎症和氧化应激,对于开发有效的治疗方法至关重要.
- 像CX-10这样的Andrographis paniculata衍生品,由于它们已知的抗炎性质,显示出有希望的结果.
研究的目的:
- 评估CX-10的治疗潜力,一个andrographolide衍生物,在硫酸 (DSS) 诱导的性结肠炎 (UC) 的小鼠模型中.
- 研究CX-10对关键UC病变发生路径的影响,包括自,氧化应激和炎症.
- 评估CX-10对自相关基因表达和自流动的影响.
主要方法:
- 一个DSS诱导的小鼠模型被用来模仿UC.
- 通过监测体重,疾病活动指数 (DAI) 和组织病理学得分来评估CX-10治疗疗效.
- 在体内和体外模型中,使用qRT-PCR,西部斑块和DCFDA检测分析了自,内质网膜 (ER) 应激和氧化应激标记.
主要成果:
- 治疗CX-10显著改善了DSS诱导的UC,减少了体重减轻,DAI和结肠损伤.
- 观察到与自相关的基因 (Becn1,Atg5) 的恢复和增强的自流量 (LC3-II/I比率).
- 在结肠组织和细胞系中,CX-10降低了ER压力标志物 (GRP78,CHOP) 和减少反应性氧物种 (ROS).
结论:
- 通过调节自和氧化应激,CX-10显示出对实验性UC的显著保护作用.
- 这些发现表明,CX-10具有作为治疗性结肠炎的新疗剂的潜力.
- 对CX-10的机制和临床疗效的进一步研究是有必要的.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
238
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
238
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Delivery Pathways to the Lysosome
7.2K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
7.2K


